Definition of peptide binding motifs amongst the HLA-A*30 allelic group

Tissue Antigens

Volumn 56, Issue 1, 2000, Pages 10-18

  Krausa, Pete ^a,f   Munz C ^b   Keilholz, W ^b   Stevanovic, S ^b   Jones, E Y ^c   Browning, M ^d   Bunce, M ^e   Rammensee, H G ^b   McMichael, A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e Oxford Transplant Centre   (United Kingdom)

^f Molecular Genetics Division   (United States)

Author keywords

HLA A30; Peptide motif

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA TRANSFECTION; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY GENE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION;

EID: 0033925353     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2000.560102.x     Document Type: Article

References (27)

1. 1. Mason PM, Parham P. HLA class I region sequences, 1998. Tissue Antigens 1998: 51: 417-66.
2. 2. Carpenter CB, Dyer P, Festenstein H et al. Antigen Society #3 Report (AW19 and A32/ Aw74). In: Dupont B, ed. Immunobiology of HLA. Histocompatibility testing 1987. New York: Springer-Verlag, 1989: 124-6.
3. 3. Kato K, Trapani JA, Allopenna J, Dupont B, Yang SY. Molecular analysis of the serologically defined HLA-Aw19 Antigens. A genetically distinct family of HLA-A antigens comprising A29, A31, A32 and Aw33, but probably not A30. J Immunol 1989: 143: 3371-8.
4. 4. Krausa P, Bodmer JG, Browning MJ. Defining the common subtypes of HLA A9, A10, A28 and A19 by use of ARMS/ PCR. Tissue Antigens 1993: 42: 91-9.
5. 5. Yang SY. Population analysis of class I HLA antigens by one-dimensional isoelectric gel electrophoresis: workshop summary report. In: Dupont B, ed. Immunobiology of HLA. Histocompatibility testing 1987. New York: Springer-Verlag, 1989: 309-31.
6. 6. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA System, 1996. Hum Immunol 1997: 53: 98-128.
7. 7. Krausa P, McAdam S, Bunce M et al. HLA-A, -B, -C, DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Exp Clin Immunogenet 1999: 16: 17-25.
8. 8. Krausa P, Carcassi C, Orrú S et al. Defining the allelic variants of HLA-A30 in the Sardinian population using amplification refractory mutation system-polymerase chain reaction. Hum Immunol 1995: 44: 35-44.
9. 9. Edwards PA, Smith CM, Neville AM, O'Hare MJ. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982: 12: 641-8.
10. 10. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987: 138: 1657-9.
11. 11. Zemmour J, Little A-M, Schendel DJ, Parham P. The HLA-A, B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992: 148: 1941-8.
12. 12. Brodsky F, Parham P, Barnstable C, Crumpton M, Bodmer W. Monoclonal antibodies for analysis of the HLA system. Immunol Rev 1979: 47: 3-61.
13. 13. Mazzoleni O, Pistillo M, Falco M, Tazzari P, Ferrara G. Characterization of two human monoclonal antibodies recognizing HLA-A30 and HLA-A3+A31, respectively. Tissue Antigens 1991: 38: 224-7.
14. 14. Terasaki PI, McClelland JD. Microdoplet assay of human serum cytotoxins. Nature 1964: 204: 998-1007.
15. 15. Bodmer WF, Bodmer JG. Cytofluorochromasia for HLA-A, -B, -C and DR typing. In: Ray JG, ed. NIAID manual of tissue typing techniques 1979-1980. NIH. Bethesda: NIH, 1979: 46-54.
16. 16. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991: 351: 290-6.
17. 17. Falk K, Rotzschke O, Takiguchi M et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenet 1994: 40: 238-41.
18. 18. Barouch D, Friede T, Stevanovic S et al. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 1995: 182: 1847-56.
19. 19. Rotzschke O, Falk K, Stevanovic S et al. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenet 1994: 39: 74-7.
20. 20. Falk K, Rotzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 1990: 348: 248-51.
21. 21. Bjorkman PJ, Saper MA, Samraoui B et al. Structure of the human Class I histocompatibility antigen, HLA-A2. Nature 1987: 329: 506-12.
22. 22. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993: 75: 693-708.
23. 23. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenet 1995: 41: 178-228.
24. 24. Rotzschke O, Falk K, Stevanovic S, Jung G, Rammensee HG. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992: 22: 2453-6.
25. 25. Sudo T, Kamikawaji N, Kimura A et al. Differences in MHC Class I self peptide repertoires among HLA-A2 subtypes. J Immunol 1995: 155: 4749-56.
26. 26. Kraulis I. MOLSCRIPT; a program to produce both detailed and schematic plots of protein structure. J Appl Crystallography 1991: 24: 946-50.
27. 27. Merritt EA, Murphy MEP. Raster3D version 2.0Å program for photorealistic molecular graphics. Acta Cryst 1994: D50: 869-73.